1,155 results match your criteria Fixed Drug Eruptions


[A CASE OF STEVENS-JOHNSON SYNDROME SUSPECTED BY A COMMON COLD MEDICATION AS CAUSE].

Arerugi 2022 ;71(4):328-333

Department of Pediatrics, Kasugai Municipal Hospital.

We describe here the case of a 7-year-old male patient with Stevens-Johnson syndrome (SJS), which was suspected to be caused by treatment with tipepidine hibenzate (Asverin). The day after taking tipepidine hibenzate and L-carbocysteine (Carbocysteine DS) for relief of a cold, he began presenting with the following symptoms: fever above 38°C, wheezing, and decreased oxygen saturation. Two days later, mucous membrane rashes, such as erosions on the lips, eye mucosa, vulva, and blisters on the trunk appeared, and SJS was thus diagnosed. Read More

View Article and Full-Text PDF

A Fixed Drug Eruption to Medroxyprogesterone Acetate Injectable Suspension.

Cutis 2022 03;109(3):E12-E14

Dr. Patel is from the Long School of Medicine, University of Texas Health San Antonio. Drs. Cervantes, Keeling, and Adamson are from the Department of Internal Medicine, Division of Dermatology, Dell Medical School at Austin, Texas.

View Article and Full-Text PDF

Patch testing in fixed drug eruptions: a 12-year retrospective study.

J Eur Acad Dermatol Venereol 2022 Jun 2. Epub 2022 Jun 2.

Dermatovenereology Department of Coimbra University Hospital, Coimbra, Portugal.

View Article and Full-Text PDF

Severe Cutaneous Adverse Drug Reactions in Children: Epidemiological, Clinical and Etiological Aspects in Dermatology-Venereology Unit at National and Teaching Hospital of Cotonou.

West Afr J Med 2022 May;39(5):538-542

Service de dermatologie-vénérologie, Centre National Hospitalier et Universitaire de Cotonou, Faculté des Sciences de la Santé - Université d'Abomey-Calavi.

Background: The aim of this study was to describe the epidemiological, clinical and etiological aspects of severe cutaneous adverse drug reactions in children in dermatologyvenereology unit at National and Teaching Hospital of Cotonou.

Methods: A retrospective and descriptive study was carried out for 10 years in dermatology-venereology unit at the National and Teaching Hospital of Cotonou to document the epidemiological, clinical and etiological aspects of severe cutaneous adverse drug reactions in children. It included all children aged from 0 to 18 years with clinical diagnosis of severe cutaneous adverse drug reactions. Read More

View Article and Full-Text PDF

Fixed drug eruption from atezolizumab.

Dermatol Online J 2022 Jan 15;28(1). Epub 2022 Jan 15.

Department of Dermatology, Loma Linda University, Loma Linda, California, USA.

Fixed drug eruption (FDE) is a cutaneous drug reaction that tends to recur in the same area (fixed location) upon re-exposure to the offending agent. We present a 48-year-old woman with FDE being treated for metastatic breast cancer with atezolizumab. We believe this is the first reported case of FDE secondary to atezolizumab. Read More

View Article and Full-Text PDF
January 2022

Oral fixed drug eruption: Analyses of reported cases in the literature.

J Stomatol Oral Maxillofac Surg 2022 Apr 17. Epub 2022 Apr 17.

Dentistry Student, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:

Background: This analytic study aimed to summarize the data regarding OFDEs manifestations and characteristics available up to date.

Materials And Methods: We searched online databases for relevant articles and summarized their data regarding age, gender, Main drug classification and name, additional drugs, dosages, primary disorders, OFDE presentation and location, extra-oral presentation and location, follow-up, and treatment.

Results: The mean age of OFDE-affected patients was 38. Read More

View Article and Full-Text PDF

Another case of generalized bullous fixed drug eruption following an adenoviral vector-based COVID-19 vaccine (ChAdOx1 nCov-19).

J Eur Acad Dermatol Venereol 2022 07 15;36(7):e516-e517. Epub 2022 Mar 15.

Dermatology, Farhat Hached Hospital, University of Sousse, Sousse, Tunisia.

View Article and Full-Text PDF

Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.

Ann Med Surg (Lond) 2022 Mar 1;75:103420. Epub 2022 Mar 1.

Internal Medicine Consultant, Medical Specialties Department, King Fahad Medical City, Riyadh, Saudi Arabia.

Introduction And Importance: Messenger RNA vaccines, commonly known as mRNA vaccines, are the first COVID-19 vaccines that have been authorized and licensed in the United States. Two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) are available. Mass vaccination remains the most critical way to halt the spread of the COVID pandemic. Read More

View Article and Full-Text PDF

Multifocal Bullous Fixed Drug Eruption.

Acta Med Port 2022 Feb 28. Epub 2022 Feb 28.

Unidade de Saúde Familiar Sem Fronteiras. Agrupamento de Centros de Saúde Entre Douro e Vouga I Feira/Arouca. Santa Maria da Feira. Serviço de Dermatologia. Centro Hospitalar e Universitário do Porto. Porto. Instituto de Ciências Biomédicas Abel Salazar. Porto. Portugal.

View Article and Full-Text PDF
February 2022

A Case of Mucosal Fixed Drug Eruption Caused by Tamsulosin Administration.

Ann Dermatol 2022 Feb 27;34(1):63-65. Epub 2022 Jan 27.

Department of Dermatology, Chosun University College of Medicine, Gwangju, Korea.

Fixed drug eruption (FDE) is a rare type of drug reaction that involves the skin and, less commonly, the mucosal membranes. It is characterized by clinically well-defined erythematous patches or plaques with or without blisters, which relapse at the same location if the causative agent is readministered. Tamsulosin is an alpha-1 adrenergic receptor blocker used to treat benign prostatic hyperplasia, and its common side effects are dizziness and headache. Read More

View Article and Full-Text PDF
February 2022

Mucosal fixed drug eruption to levetiracetam with early positive patch test on non-lesional skin.

Authors:
Nazli Ercan

Pediatr Allergy Immunol 2022 02;33(2):e13723

Division of Pediatric Allergy and Immunology, Department of Pediatrics, Gulhane Research and Training Hospital, University of Health Sciences Turkey, Ankara, Turkey.

View Article and Full-Text PDF
February 2022

Fixed drug eruption in a patient of HLA-B*58:01 negative after allopurinol administration: A case report.

J Clin Pharm Ther 2022 Jun 3;47(6):841-843. Epub 2022 Feb 3.

Department of Geriatrics, Peking University First Hospital, Beijing, China.

What Is Known And Objective: Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). HLA-B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol-induced CADRs, especially for Asian descents.

Case Summary: A 60-year-old Chinese Han male patient took allopurinol for lowering uric acid after the negative result from HLA-B*58:01 testing. Read More

View Article and Full-Text PDF

The Role of Patch Testing in Evaluating Delayed Hypersensitivity Reactions to Medications.

Clin Rev Allergy Immunol 2022 Jun 3;62(3):548-561. Epub 2022 Feb 3.

University of California San Francisco, San Francisco, CA, USA.

Confirming drug imputability is an important step in the management of cutaneous adverse drug reactions (CADR). Re-challenge is inconvenient and in many cases life threatening. We review the literature on ideal patch testing technique for specific CADRs. Read More

View Article and Full-Text PDF

Neutrophils in Fixed Drug Eruptions: Correction of a Mistaken Hypothesis.

Am J Dermatopathol 2022 Feb;44(2):106-110

Dermatology/Dermatopathology, University of Pittsburgh, Pittsburgh, PA.

Abstract: Classical histopathological findings of fixed drug eruption (FDE) include a lichenoid/interface dermatitis and perivascular infiltrate in the upper and deep dermis composed of lymphocytes and eosinophils accompanied by pigment incontinence. The presence of neutrophils is also an established finding but is less investigated. Sporadic cases of "neutrophilic FDE" have been reported and suggested as a separate entity, a rare variant, or an early stage of the condition. Read More

View Article and Full-Text PDF
February 2022

Patch Testing in Drug Eruptions: Practical Aspects and Literature Review of Eruptions and Culprit Drugs.

Authors:
Anton C de Groot

Dermatitis 2022 Jan-Feb 01;33(1):16-30

Abstract: There is overwhelming evidence that many delayed cutaneous adverse drug reactions (beginning >6 hours after drug intake) are mediated by delayed-type (type IV) hypersensitivity, including maculopapular eruptions, erythroderma, symmetrical drug-related intertriginous and flexural exanthema/baboon syndrome, eczematous eruptions, fixed drug eruptions, acute generalized exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome. Therefore, after resolution of the reaction, patch tests should be performed as first diagnostic method to identify the culprit drug(s). This article provides tools to perform drug patch tests properly and safely, discussing clinical history, indications, procedure, drug patch test materials, sensitivity, the meaning of negative patch tests, and safety of the procedure. Read More

View Article and Full-Text PDF
February 2022

Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole.

Clin Rev Allergy Immunol 2022 Jun 15;62(3):463-475. Epub 2021 Dec 15.

University of California San Diego and Rady Children's Hospital, San Diego, CA, USA.

Hypersensitivity reactions including IgE-mediated and delayed cell-mediated reactions to aminoglycosides, clindamycin, linezolid, and metronidazole are rare. For aminoglycosides, allergic contact dermatitis is the most frequent reaction for which patch testing can be a useful step in evaluation. For clindamycin, delayed maculopapular exanthems are the most common reactions. Read More

View Article and Full-Text PDF

A Study of Cutaneous Adverse Drug Reactions and their Association with Autoimmune Diseases at a Tertiary Centre in South-West Rajasthan, India.

Indian J Dermatol 2021 Jul-Aug;66(4):445

Department of Pharmacy, Geetanjali Medical College and Hospital, Udaipur, India.

Background: Cutaneous adverse drug reactions (CADRs) comprise about 30% of all adverse drug reactions and observed in 2-3% of hospitalized patients by wide variety of offending agents.

Aims: To study the clinical patterns, causative drugs and their association with autoimmune diseases in CADR patients.

Materials And Methods: A total of 174 CADR patients who presented to the dermatology OPD over a period of 18 months (1 July 2015 to 31 Dec 2016) were considered for the study. Read More

View Article and Full-Text PDF
November 2021

Patch testing versus interferon-gamma release assay in evaluation of drug eruptions.

Fundam Clin Pharmacol 2022 Apr 26;36(2):414-420. Epub 2021 Oct 26.

Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Delayed-onset T-cell-mediated cutaneous adverse drug reactions are an uncommon but potentially serious result of medication exposures. Identification of culprit medications is crucial, but clinical diagnosis is often difficult. Patch tests and interferon-gamma release assays (IFNγ-RA) were previously reported as potentially useful ancillary tests, while rechallenges remain the reference standard test. Read More

View Article and Full-Text PDF

Multiple fixed drug eruption due to carbocysteine: Presence of circulating interferon-γ-producing CD8 T cells reactive with its night metabolite thiodiglycolic acid.

Allergol Int 2022 04 9;71(2):256-258. Epub 2021 Oct 9.

Department of Dermatology & Skin Oncology, Chutoen General Medical Center, Kakegawa, Japan; Allergic Disease Research Center, Chutoen General Medical Center, Kakegawa, Japan. Electronic address:

View Article and Full-Text PDF

Vulvar and areolar fixed drug eruption.

Am J Obstet Gynecol 2022 04 2;226(4):566. Epub 2021 Oct 2.

Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Department of Dermatology, Universitat de València, Valencia, Spain.

View Article and Full-Text PDF

A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption.

Medicina (Kaunas) 2021 Sep 1;57(9). Epub 2021 Sep 1.

Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by the onset of rash at a fixed location on the body each time a specific medication is ingested. With each recurrence, the eruption can involve additional sites. Lesions can have overlying vesicles and/or bullae, and when they cover a significant percentage of body surface area, the eruption is referred to as generalized bullous fixed drug eruption (GBFDE). Read More

View Article and Full-Text PDF
September 2021

Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination.

Clin Exp Dermatol 2022 02 10;47(2):428-432. Epub 2021 Oct 10.

Division of Dermatology, Skin and Allergy Research Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

View Article and Full-Text PDF
February 2022

Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine.

BMJ Case Rep 2021 Aug 19;14(8). Epub 2021 Aug 19.

Sanford Health North, Fargo, North Dakota, USA.

A 51-year-old woman with Crohn's disease presented with a bullous rash on her left arm and axilla 2 days after receiving her second dose of the recombinant adjuvant Shingrix vaccine. PCR for herpes simplex virus (HSV) 1, HSV 2 and varicella zoster virus was negative. Punch biopsy revealed changes that were consistent with a bullous fixed drug eruption. Read More

View Article and Full-Text PDF

Tylenol or acetaminophen: a recurrent fixed drug eruption perpetuated through the use of inconsistent drug terminology.

BMJ Case Rep 2021 Aug 3;14(8). Epub 2021 Aug 3.

Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA

An 87-year-old man with a history of osteoarthritis presented with worsening knee pain. He was prescribed acetaminophen with codeine. A few days later, he developed a rash on his right buttock and proximal thigh, similar to a rash he experienced in the past when he took over-the-counter (OTC) acetamenophen and an unknown lozenge to treat a presumed viral illness. Read More

View Article and Full-Text PDF

Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms.

Eur J Dermatol 2021 Jun;31(3):372-380

Pathology department, Henri Mondor hospital, AP-HP, 94010 Créteil Cedex, France, Intensive care unit, Henri Mondor hospital, AP-HP, 94010 Créteil Cedex, France, Reference centre for toxic bullous diseases and severe cutaneous adverse reactions TOXIBUL, Créteil, France.

The clinical and pathological aspects of fixed drug eruption (FDE) have been described based on a few case series. To compare bullous FDE (BFDE) and non-bullous FDE (NBFDE) and to determine whether BFDE can be histologically distinguished from other dermatoses presenting with an apoptotic pan-epidermolysis. In this retrospective monocentre study (2005-2016), FDE was classified as BFDE or NBFDE and localized (one anatomical site) or generalized (≥ two sites; GBFDE). Read More

View Article and Full-Text PDF

Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report.

J Infect Public Health 2021 Oct 8;14(10):1392-1394. Epub 2021 Jul 8.

Icahn School of Medicine at Mount Sinai/NYC Health + Hospitals Queens, NY, USA. Electronic address:

Background: In December 2020, Moderna released the mRNA-1273 vaccine. The most common side effects are headache, muscle pain, redness, swelling, and tenderness at the injection site. In addition, there have been dermatological adverse events, such as hypersensitivity reactions. Read More

View Article and Full-Text PDF
October 2021

Two cases of quinine-induced fixed 'drug' eruption induced by long drinks.

J Eur Acad Dermatol Venereol 2021 Nov 2;35(11):e774-e776. Epub 2021 Jul 2.

Department of Dermatology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

View Article and Full-Text PDF
November 2021